Viking Therapeutics (VKTX) — the peer cohort

As of 2026-10-19 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Viking Therapeutics ranks 16 of 16 in its cohort on the Closelooknet composite (27/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

Name	Composite	Momentum	Quality	Valuation	Signal	Off 52w high
VKTX Viking Therapeutics	27	17	2	—	bear	41.7%
WISE.L Wise	67	31	81	56	bear	26.7%
DECK Deckers Outdoor	66	17	80	75	neutral	29.9%
DXCM Dexcom	66	86	81	36	watch	7.1%
RACE Ferrari	66	73	83	27	bear	20.3%
LLY Eli Lilly	65	83	91	28	bull	2.8%
TOST Toast	62	64	51	44	bear	25%
FSLR First Solar	61	21	73	74	bear	46.2%
REGN Regeneron	61	74	72	50	watch	8%
GMED Globus Medical	60	36	66	57	watch	24.3%
HDB HDFC Bank	60	31	69	80	neutral	34.3%
DB1.DE Deutsche Börse	59	86	81	39	bull	0.2%
HALO Halozyme Therapeutics Inc	74	98	94	49	ok	0.5%
BION.SW BB Biotech AG	73	58	96	81	info	15.5%
ONC BeiGene, Ltd.	65	83	65	32	ok	4.2%
RIGL Rigel Pharmaceuticals Inc	62	86	90	75	info	12%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-19

Quick answers

Who are Viking Therapeutics's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Wise (WISE.L), Deckers Outdoor (DECK), Dexcom (DXCM), Ferrari (RACE), Eli Lilly (LLY), Toast (TOST), First Solar (FSLR), Regeneron (REGN) and others.

How does VKTX score against its peers?

Viking Therapeutics's composite reads 27/100, ranking 16 of 16 in its cohort as of 2026-10-19; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.